The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy ; use as a single agent in susceptible patients ; techniques used to identify susceptible patients

  • Sydney Shall
  • , Terry Gaymes
  • , Farzin Farzaneh
  • , Nicola Curtin
  • , Ghulam J. Mufti

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    Abstract

    This chapter describes some of the techniques in use in our laboratories for the investigation of PARP inhibitors in clinical medicine. More specifically, we are involved in investigating the utility of PARP inhibitors in the treatment of hematopoietic malignancies. We are also actively investigating the properties of the PARP systems in cell biology. We begin the chapter with a very brief history of the invention and use of PARP inhibitors. We then explain the underlying logic of the use of PARP inhibitors either in combination with chemo- or radiotherapy or as single agents used alone. We then provide in full detail the protocols that we use to study PARP inhibitors in cell biology to identify patients that should be susceptible to PARP inhibitor treatment and to manage and investigate these patients throughout their treatment.
    Original languageEnglish
    Title of host publicationPoly(ADP-Ribose) Polymerase
    Subtitle of host publicationMethods and Protocols
    EditorsAlexei V. Tulin
    Place of PublicationNew York, NY
    PublisherSpringer
    Pages239-266
    ISBN (Print)9781617792700
    Publication statusPublished - 2011

    Publication series

    NameMethods in Molecular Biology
    PublisherSpringer

    Keywords

    • Biological sciences
    • DNA repair
    • Leukemia
    • PARP
    • PARP inhibitors
    • cancer
    • repair of double-stranded DNA breaks

    Fingerprint

    Dive into the research topics of 'The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy ; use as a single agent in susceptible patients ; techniques used to identify susceptible patients'. Together they form a unique fingerprint.

    Cite this